menu
    • menu
    [{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Durbin","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Durbin","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Durbin"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"SIFI","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ Inapplicable"},{"orgOrder":0,"company":"Avanzanite Bioscience","sponsor":"SIFI","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"NETHERLANDS","productType":"Other Small Molecule","year":"2023","type":"Licensing Agreement","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Avanzanite Bioscience","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"Avanzanite Bioscience \/ SIFI","highestDevelopmentStatusID":"10","companyTruncated":"Avanzanite Bioscience \/ SIFI"},{"orgOrder":0,"company":"SIFI","sponsor":"University of California","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2025","type":"Collaboration","leadProduct":"Polyhexanide","moa":"Acanthamoeba cell membrane","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"SIFI","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Ophthalmic Solution","sponsorNew":"SIFI \/ University of California","highestDevelopmentStatusID":"15","companyTruncated":"SIFI \/ University of California"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Best Buy Medical Canada","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2025","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Best Buy Medical Canada","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Best Buy Medical Canada"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"BioStem Technologies","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Partnership","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ BioStem Technologies","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ BioStem Technologies"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Qatar Datamation Systems","pharmaFlowCategory":"D","therapeuticArea":"Podiatry","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Agreement","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Podiatry","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Topical Gel","sponsorNew":"Kane Biotech \/ Qatar Datamation Systems","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Qatar Datamation Systems"},{"orgOrder":0,"company":"Kane Biotech","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Trauma (Emergency, Injury, Surgery)","country":"CANADA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Polyhexanide","moa":"||Acanthamoeba cell membrane","graph1":"Trauma (Emergency, Injury, Surgery)","graph2":"Approved FDF","graph3":"Kane Biotech","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Trauma","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kane Biotech \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Kane Biotech \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Polyhexanide

    Menu

    Polyhexanide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    MARKET PLACE

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Approved FDF

                            Sponsor : University of California

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            SIFI, UCSF Collaborate on Acanthamoeba Keratitis Research

                            Details : The collaboration aims to evaluate the Akantior (polihexanide), the first and only approved drug for the treatment of AK. It is being indicated for the treatment of Acanthamoeba Keratitis in US.

                            Product Name : Akantior

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 18, 2025

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Approved FDF

                            Sponsor : University of California

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Best Buy Medical Canada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Announces Canadian Distribution Agreement with Best Buy Medical for Revyve

                            Details : The agreement aims for the distribution of revyve, an antimicrobial wound gel product line in infection management and wound healing.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            March 11, 2025

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Best Buy Medical Canada

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SIFI Updates AKANTIOR® Regulatory Pathway for Acanthamoeba Keratitis in UK and US

                            Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.

                            Product Name : Akantior

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 16, 2024

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Kane Biotech Changes US Partner for Revyve™ Antimicrobial Wound Gel Distribution

                            Details : BioStem Technologies will acquire exclusive US distribution rights for revyve from ProgenaCare Global.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            November 27, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : BioStem Technologies

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Kane Biotech Announces Health Canada Approval of revyve™ Antimicrobial Wound Gel

                            Details : Revyve Antimicrobial Wound Gel is indicated for management of ulcers (including diabetic foot and leg ulcers and pressure ulcers), burns, partial & full thickness wounds for adult populations.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 14, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Trauma (Emergency, Injury, Surgery)

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed

                            Kane Biotech

                            Canada arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Study Phase : Approved FDF

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kane Biotech Signs Deal with Qatar Datamation For Wound Gel Distribution

                            Details : The agreement aims for the distribution of revyve antimicrobial wound gel indicated for diabetic foot ulcers, in the Qatar wound care market.

                            Product Name : Revyve

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            August 28, 2024

                            Lead Product(s) : Polyhexanide,Citric Acid,Edetate Calcium Disodium

                            Therapeutic Area : Podiatry

                            Highest Development Status : Approved FDF

                            Sponsor : Qatar Datamation Systems

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SIFI Receives European Commission Approval for AKANTIOR®

                            Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that got approval from european medicines agency for the treament of acanthamoeba keratitis.

                            Product Name : Akantior

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 26, 2024

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SIFI Receives Positive Opinion for Orphan Drug Designation for Polihexanide

                            Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

                            Product Name : Akantior

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            July 22, 2024

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis

                            Details : Akantior® (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

                            Product Name : Akantior

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 31, 2024

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed

                            SIFI

                            Italy arrow
                            AACR Annual meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Avanzanite’s AKANTIOR® Gets Positive CHMP Opinion and Expands into 26 European Countries

                            Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.

                            Product Name : Akantior

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 06, 2024

                            Lead Product(s) : Polyhexanide

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth